CJC 1295 (without DAC) + IPA
Paired GH-axis research blend.
- Vial Size
- 10mg
- Molecular Weight
- Blend · CJC 3367.9 g/mol + IPA 711.85 g/mol
- Half-life
- CJC-1295 (no DAC) ~30 min · Ipamorelin ~2 hours
- Latest Lot Purity
- 99.62%
Mechanism of Action
Paired GH-axis research blend. CJC-1295 (without DAC) is a GHRH analogue; Ipamorelin is a selective ghrelin-receptor agonist. The combination is studied for synergistic, pulsatile growth-hormone release in research models.
Research Context
- Growth hormone pulsatility studies
- Body-composition research models
- GH-axis pharmacology research
- Recovery and protein-synthesis research
Plasma Profile & Protocol
Modelled plasma concentration over time, reconstitution calculator, and a literature-derived research protocol for CJC 1295 (without DAC) + IPA.
Illustrative Bateman model derived from published half-life and absorption data. For research-context visualisation only.
Solve for syringe units assuming a U-100 insulin syringe. Defaults seeded from the CJC 1295 (without DAC) + IPA monograph.
U-100 insulin syringe assumed (100 units = 1 mL). For research dosing visualisation only. Verify all dilutions independently.
- Typical Dose
- 100 mcg CJC + 100 mcg IPA
- Frequency
- 1–3× daily, pre-sleep + AM
- Cycle Length
- 8–12 weeks
- Route
- Subcutaneous
Note ·Saturation dose; pulsatile release modelled across 2-hour window.
Related Compounds
All compounds →
HGH Fragment 176-191
Lipolytic GH fragment for body-composition research models.
Tesamorelin
GHRH analog supporting advanced metabolic and visceral adipose research.
Ipamorelin
Selective growth hormone secretagogue for protocol layering.
For Research Use Only · This monograph summarises publicly available research literature for educational, in-vitro and laboratory research purposes only. Nexora Labs products are not drugs, food, supplements, or cosmetics, and are not intended to diagnose, treat, cure or prevent any condition.